Browse our 650+ Publications​

Latest Publications

Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma

Cascini C, et al.
Journal of Experimental Medicine
August 2023
Authors and Affiliates
Caterina Cascini 1, Chiara Ratti 1, Laura Botti 1, Beatrice Parma 1, Valeria Cancila 2, Adriana Salvaggio 1, Cristina Meazza 3, Claudio Tripodo 2 4, Mario P Colombo 1, Claudia Chiodoni 5; 1 Department of Experimental Oncology, Molecular Immunology Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Amadeo 42, 20133, Milan, Italy. 2 Department of Health Science, Tumor Immunology Unit, University of Palermo School of Medicine, Palermo, Italy. 3 Pediatric Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy. 4 IFOM, FIRC Institute of Molecular Oncology, Milan, Italy. 5 Department of Experimental Oncology, Molecular Immunology Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Amadeo 42, 20133, Milan, Italy. claudia.chiodoni@istitutotumori.mi.it.

A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer

Page DB, et al.
NPJ Breast Cancer
August 2023
Authors and Affiliates
David B Page 1, Joanna Pucilowska 2, Brie Chun 2, Isaac Kim 2, Katherine Sanchez 2, Nicole Moxon 2, Staci Mellinger 2, Yaping Wu 2, Yoshinobu Koguchi 2, Valerie Conrad 2, William L Redmond 2, Maritza Martel 2, Zhaoyu Sun 2, Mary B Campbell 2, Alison Conlin 2, Anupama Acheson 2, Reva Basho 3,4, Philomena McAndrew 3, Mary El-Masry 3, Dorothy Park 3, Laura Bennetts 2, Robert S Seitz 5, Tyler J Nielsen 5, Kimberly McGregor 5, Venkatesh Rajamanickam 2, Brady Bernard 2, Walter J Urba 2, Heather L McArthur 3,6; 1 Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA. david.page2@providence.org. 2 Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA. 3 Cedars Sinai Medical Center, Los Angeles, CA, USA. 4 Ellison Institute for Transformative Medicine, Los Angeles, CA, USA. 5 Oncocyte Corporation, Irving, CA, USA. 6 UT Southwestern Medical Center, Dallas, TX, USA.

GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for ≥6 months in previously-vaccinated older adults

Palmer CD, et al.
Nature Communications
August 2023
Authors and Affiliates
Christine D Palmer 1, Ciaran D Scallan 1, Lauren D Kraemer Tardif 1, Melissa A Kachura 1, Amy R Rappaport 1, Daniel O Koralek 1, Alison Uriel 2, Leonid Gitlin 1, Joshua Klein 1, Matthew J Davis 1, Harshni Venkatraman 1, Meghan G Hart 1, Jason R Jaroslavsky 1, Sonia Kounlavouth 1, Martina Marrali 1, Charmaine N Nganje 1, Kyounghwa Bae 1, Tiffany Yan 1, Katharyn Leodones 1, Milana Egorova 1, Sue-Jean Hong 1, Jenchun Kuan 1, Silvia Grappi 3, Pedro Garbes 1, Karin Jooss 4, Andrew Ustianowski 2; 1 Gritstone bio, Inc., Emeryville, CA, USA. 2 North Manchester General Hospital & University of Manchester, Manchester, UK. 3 VisMederi Srl., Siena, Italy. 4 Gritstone bio, Inc., Emeryville, CA, USA. kjooss@gritstone.com.

Cell surface marker-based capture of neoantigen-reactive CD8+ T-cell receptors from metastatic tumor digests

Chatani PD, et al.
Journal for ImmunoTherapy of Cancer
August 2023
Authors and Affiliates
Praveen D Chatani 1, Frank J Lowery 2, Neilesh B Parikh 1, Kyle J Hitscherich 1, Rami Yossef 1, Victoria Hill 1, Jared J Gartner 1, Biman Paria 1, Maria Florentin 1, Satyajit Ray 1, Alakesh Bera 1, Maria Parkhust 1, Paul Robbins 1, Sri Krishna 2, Steven A Rosenberg 2; 1 Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. 2 Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA sri.krishna@nih.gov frank.lowery@nih.gov sar@mail.nih.gov.

Statistical inference reveals the role of length, GC content, and local sequence in V(D)J nucleotide trimming

Russell ML, et al.
eLIFE
August 2023
Authors and Affiliates
Magdalena L Russell 1,2, Noah Simon 3, Philip Bradley 1,4, Frederick A Matsen 4th 1,5,6,7; 1 Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, United States. 2 Molecular and Cellular Biology Program, University of Washington, Seattle, United States. 3 Department of Biostatistics, University of Washington, Seattle, United States. 4 Institute for Protein Design, Department of Biochemistry, University of Washington, Seattle, United States. 5 Department of Genome Sciences, University of Washington, Seattle, United States. 6 Department of Statistics, University of Washington, Seattle, United States. 7 Howard Hughes Medical Institute, Seattle, United States.

Single-cell atlas of the human neonatal small intestine affected by necrotizing enterocolitis

Egozi A, et al.
PLOS Biology
August 2023
Authors and Affiliates
Adi Egozi 1, Oluwabunmi Olaloye 2, Lael Werner 3,4, Tatiana Silva 2, Blake McCourt 2, Richard W Pierce 2,5, Xiaojing An 6, Fujing Wang 6, Kong Chen 6, Jordan S Pober 5,7, Dror Shouval 3,4, Shalev Itzkovitz 1, Liza Konnikova 2,5,7,8; 1 Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel. 2 Department of Pediatrics, Yale School of Medicine, New Haven, Connecticut, United States of America. 3 Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center of Israel, Petah Tikva, Israel, affiliated to the Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 4 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 5 Program in Human and Translational Immunology, Yale School of Medicine, New Haven, Connecticut, United States of America. 6 Department of Medicine, University of Pittsburgh Medical Center Montefiore Hospital, Pittsburgh, Pennsylvania, United States of America. 7 Department of Immunobiology, Yale School of Medicine, New Haven, Connecticut, United States of America. 8 Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut, United States of America.

Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells

Islam SMR, et al.
Cancer Research Communication
August 2023
Authors and Affiliates
S M Rafiqul Islam 1,2, Takuya Maeda 1,2, Naritaka Tamaoki 1,2, Meghan L Good 1,2, Rigel J Kishton 1,2, Biman C Paria 1, Zhiya Yu 1, Marta Bosch-Marce 1, Nicole M Bedanova 3, Chengyu Liu 4, Michael J Kruhlak 5, Nicholas P Restifo 1,2, Raul Vizcardo 1,2; 1 Surgery Branch, NCI, NIH, Bethesda, Maryland. 2 Center for Cell-Based Therapy, NCI, NIH, Bethesda, Maryland. 3 Experimental Pathology Laboratory, NCI, NIH, Bethesda, Maryland. 4 Transgenic Core, Division of Intramural Research, National Heart, Lung and Blood Institute, NIH, Bethesda, Maryland. 5 CCR Microscopy Core Facility, NCI, NIH, Bethesda, Maryland.

Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial

Tang C, et al.
JAMA Oncology
August 2023
Authors and Affiliates
Chad Tang 1,2,3, Alexander D Sherry 1, Cara Haymaker 2, Tharakeswara Bathala 4, Suyu Liu 5, Bryan Fellman 5, Lorenzo Cohen 6, Ana Aparicio 7, Amado J Zurita 7, Alexandre Reuben 8, Enrica Marmonti 2, Stephen G Chun 1, Jay P Reddy 1, Amol Ghia 1, Sean McGuire 1, Eleni Efstathiou 7, Jennifer Wang 7, Jianbo Wang 7, Patrick Pilie 7, Craig Kovitz 7, Weiliang Du 9, Samantha J Simiele 9, Rachit Kumar 10, Yerko Borghero 10, Zheng Shi 11, Brian Chapin 12, Daniel Gomez 13, Ignacio Wistuba 2, Paul G Corn 7; 1 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston. 2 Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston. 3 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston. 4 Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston. 5 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston. 6 Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston. 7 Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston. 8 Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston. 9 Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston. 10 Department of Radiation Oncology, Banner MD Anderson Cancer Center, Gilbert, Arizona. 11 Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio. 12 Department of Urology, The University of Texas MD Anderson Cancer Center, Houston. 13 Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy

Jaber A, et al.
Neurology and Therapy
August 2023
Authors and Affiliates
Aliya Jaber 1, Meera Patel 1, Andrew Sylvester 1, Mary Yarussi 1, J Tamar Kalina 2, Jason P Mendoza 2, Robin L Avila 2, Matthew A Tremblay 3; 1 Multiple Sclerosis Comprehensive Care Center, RWJ Barnabas Health, Livingston, NJ, USA. 2 Biogen, Weston, MA, USA. 3 Multiple Sclerosis Comprehensive Care Center, RWJ Barnabas Health, Livingston, NJ, USA. Matthew.Tremblay@rwjbh.org.

Achievement of operational tolerance in a pediatric liver transplant recipient following successful hematopoietic stem cell transplantation from a different donor

Algeri M, et al.
American Journal of Transplantation
August 2023
Authors and Affiliates
Mattia Algeri 1, Enrico Velardi 1, Marco Spada 2, Federica Galaverna 1, Roberto Carta 1, Luciana Vinti 1, Giuseppe Palumbo 3, Stefania Gaspari 1, Andrea Pietrobattista 4, Emilia Boccieri 1, Marco Becilli 1, Paola Francalanci 5, Valentina Bertaina 1, Pietro Merli 1, Franco Locatelli 6; 1 Department of Pediatric Hematology and Oncology,Cell and Gene Therapy,Bambino Gesù Children's Hospital,IRCCS,Rome,Italy. 2 Hepatobiliopancreatic Surgery, Liver and Kidney Transplantation Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. 3 Department of Pediatric Hematology and Oncology,Cell and Gene Therapy,Bambino Gesù Children's Hospital,IRCCS,Rome,Italy; University Department of Pediatrics, Bambino Gesù Children's Hospital, University of Rome Tor Vergata, Rome, Italy. 4 Department of Pathology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. 5 Hepatology and Liver Transplant Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. 6 Department of Pediatric Hematology and Oncology,Cell and Gene Therapy,Bambino Gesù Children's Hospital,IRCCS,Rome,Italy; Department of Life Sciences and Public Health, Catholic University of the Sacred Heart, Rome, Italy. Electronic address: franco.locatelli@opbg.net.
Previous Next